(S)-2-Methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid

CAS : 475479-34-6

Ref. 3D-FA138801

Informations sur le produit

• Nom: (S)-2-Methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid
• Synonymes: Aleglitazar, (2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid, (αS)-α-Methoxy-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzo[b]thiophene-7-propanoic acid, Benzo[b]thiophene-7-propanoic acid, α-methoxy-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, (αS)-, R 1439, Ro 0728804

Description

(S)-2-Methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid is a potent inhibitor of dipeptidyl peptidase 4 (DPP4), which is an enzyme that breaks down the incretin hormone glucagon-like peptide 1. The drug has been shown to reduce body weight in obese patients and improve glycemic control in type 2 diabetes. It also inhibits the chemoattractant protein CXCL12, which may contribute to its role as a chemotherapeutic treatment for cancer. This drug has been shown to have no effect on heart rate or blood pressure in healthy volunteers. However, it has been reported to cause cardiac arrhythmia and congestive heart failure in animal studies. There are not enough data about the effects of this drug on human health to determine its

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 437.51 g/mol
• Formule: C₂₄H₂₃NO₅S
• Degré de pureté: Min. 95%